One of the problems of one embodiment of the present invention is to provide film-coated granules which have a new film constitution. Alternatively, one of the problems of one embodiment of the present invention is to provide a pharmaceutical preparation containing the film-coated granules which have a new film constitution. Alternatively, one of the problems of one embodiment of the present invention is to provide a new dry manufacturing method of the film-coated granules. Alternatively, one of the problems of one embodiment of the present invention is to provide a new dry manufacturing method of the pharmaceutical preparation containing the film-coated granules. According to one embodiment of the present invention, a film-coated granule is provided that comprises a core particle having a melt component, and a film arranged on a surface of the core particle, wherein the film includes a porous substance, a plasticizer and a polymer.

Embodiments of the invention provide solid controlled-release penetrating member for exposure to the intestinal lumen environment and delivery of an active agent across or within the small intestine lumen wall and having a tissue penetrating tip, especially advantageous for active agents typically administered by injection. Optionally, the penetrating members include a tip coat or water insoluble extension of the controlled release formulation and/or an intestine environment protective component. Methods of using the penetrating members and arrays thereof are also provided.

A method for producing at least one microneedle containing a vaccine for transdermal delivery of the vaccine to a patient includes preparing microparticles or nanoparticles of encapsulated vaccine by preparing a solution comprising a vaccine antigen and a biocompatible polymer matrix; and spray drying the solution to form the microparticles or nanoparticles. The method includes the further steps of preparing a film composition including at least one pre-polymer solution; preparing a suspension comprising the microparticles or nanoparticles and the film composition; loading the suspension into a 3D printer; printing, via the 3D printer, at least one microneedle made from the suspension; and, converting the pre-polymer solution into a cross-linked biopolymer by exposing the at least one microneedle to UV light. Also disclosed are microneedles containing a vaccine for transdermal delivery.

In one aspect, the disclosure relates to relates to compositions, devices, and processes for drug delivery to an eye. The disclosed drug delivery compositions comprise a particle having a core component comprising a first polymer and a therapeutic agent, and a shell layer surrounding the core component comprising a second polymer. In a further aspect, the present disclosure relates to methods of treating an ophthalmological disease or disorder. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The present invention relates to extended-release suspension composition. The present invention specifically relates to extended-release suspension composition comprising active ingredient and pharmaceutically acceptable excipients, wherein said composition is in the form of powder for suspension or a ready to use suspension. The present invention specifically relates to extended-release suspension composition comprising active ingredient and pharmaceutically acceptable excipients, wherein said composition is devoid of uncoated active ingredient-ion exchange resin complex portion and polyvinyl acetate. The present invention also relates to extended-release suspension composition comprising one or more functional barrier coatings on active ingredient-ion exchange resin complex, wherein said functional barrier coatings comprises hypromellose and/or talc.

A microcapsule which is used in tissue regeneration, which may be specifically directed to the damaged tissues, and which forms an extracellular matrix-like structure at a certain point and thus allows cell proliferation.

The invention relates to floating drug delivery systems (FDDS) that provide solutions to the particular problems often encountered with floating drug delivery systems described in the art. On such generally recognized problem is the vulnerability of the systems, especially damage to the gas-filled compartment making it accessible to water so as to impair its buoyancy, ultimately resulting in insufficient gastric residence time. The invention, in an aspect, provides a self-repairing FDDS that maintains its floating capacity after damaging. The floating drug delivery systems of the invention, furthermore, allow for incorporation of high loads of active ingredients. The floating drug delivery systems can be designed in such a way that release of active ingredient from the system occurs entirely independent from the pH of the fluid surrounding the system. Furthermore, the procedure of manufacturing the floating drug delivery system of the invention is simple and straightforward, and therefore economically attractive.

The invention provides oral vaccine formulations which deliver an antigen in the vicinity of the distal ileum and the area of the ileal Brake and/or the appendix. These vaccines are useful in the treatment and/or prevention of variety of disorders, including viral and bacterial infections and cancers. Related methods of treatment which use the oral vaccine formulations of the invention are also provided.

The present invention provides a cannulation device for administering an active agent containing composition to the suprachoroidal space or supraciliary space. The invention provides methods of treatment of an ocular disease or condition accordingly. The invention also provides compositions for use in a method of treatment of an ocular disease or condition for delivery into the suprachoroidal space or supraciliary space.

The invention provides an oral solid formulation comprising (a) a controlled release component comprising a core comprising levodopa, wherein the core is coated with a layer of a muco-adhesive polymer and externally coated with a layer of an enteric polymer; and (b) an immediate release component comprising carbidopa and levodopa.